We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Research analysts at William Blair upped their Q4 2024 earnings estimates for Bristol-Myers Squibb in a report released on Tuesday, January 21st. William Blair analyst M. Phipps now forecasts that the ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $57.04 which represents a slight increase of $0.75 or 1.33% from the prior close of $56.29. The stock opened at $56.63 and ...

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

As of January 17 at 3:10:35 p.m. EST. Market Open.

Chuck Zodda, the managing partner and chief investment officer from Armstrong Advisory Group talks President Trump's impact ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

William Blair lowered their Q4 2024 earnings per share estimates for Incyte in a research note issued on Tuesday, January ...

Nuvalent, Inc. shares have fallen approximately 30% after promising updates on its two lead NSCLC candidates rallied the stock to all-time highs. Read the full report on the stock here.